Novel drug slows down glioma progression

Written By : Isra Zaman

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-06-06 03:30 GMT | Update On 2023-06-06 08:44 GMT

In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.

The team found the drug vorasidenib more than doubled progression-free survival in people with recurrent grade 2 glioma with IDH1 and IDH2 mutations. Compared with people who received a placebo, those who took vorasidenib went for nearly 17 more months without their cancer worsening, delaying the time before they needed to begin chemotherapy and radiation.

The study involved 331 people aged 12 and older who had been diagnosed with recurrent grade 2 glioma with the IDH1 and IDH2 mutations and who had undergone brain tumor surgery. From that group, 168 were randomly assigned to receive vorasidenib and 163 received placebos.

Among those who received vorasidenib, the disease did not progress for an average of 27.7 months, significantly longer than the 11.1 months for those who received the placebo. And among those who received vorasidenib, 85.6% went for 18 months before their next treatment, while 83.4% went for 24 months between treatments.

The disease progressed in just 28% of people receiving vorasidenib, compared to 54% of those receiving placebos. And as of September 2022, which was 30 months after the study began, 72% of patients who were in the vorasidenib group were still taking the drug and their disease had not progressed.

Reference:

Dr. Timothy Cloughesy et al,Vorasidenib in IDH1- or IDH2-mutant Low-Grade Glioma,New England Journal of Medicine,

Full View

Article Source : New England Journal of Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Isra Zaman

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Novel drug slows down glioma progression

Similar News

Can Blood Tests Replace Brain Scans for Alzheimer's? New Study Says Yes

Artificial Sweeteners Could Speed Up Brain Aging by 1.6 Years: Study Finds

Head Injuries May Raise Brain Cancer Risk: Major Studies Reveal

Tiny Gold Nanoparticles Show Promise For Early Parkinson's Disease Detection: Study Suggests

New 2025 Hypertension Guidelines Released with Stronger Focus on Brain Health and Early Intervention

Women with Down Syndrome More Vulnerable to Alzheimer's Than Men: Study Finds

Multiple Sclerosis May Begin 15 Years Earlier with Subtle Symptoms: Study Suggests

Can This Common Diabetes Drug Prevent Stroke? Emerging Data Suggests Strong Link